Clinical Trial Update: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluate the efficacy and safety of TAK-279 in adults with moderate-to-severe plaque psoriasis over 52 weeks.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• TAK-279

Snippet

Sponsor: Takeda | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED